Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
{{output}}
PSMA-targeted radiopharmaceutical therapy is an established treatment option for metastatic castration-resistant prostate cancer (mCRPC). However, response rates and duration using 177Lu-PSMA-617 vary considerably between patients. Quantitative 177Lu SPECT ima... ...
